>>Bioperle>noch unentdeckt>CHANCE+++ - 500 Beiträge pro Seite

[BillyTheKid2]

.
Zulassung von Krebsmedikament und prall gefüllte Pipline.
.
Die Chancen der Zukunft
.


Als strategischer Partner non ATRIX.
.
Siehe auch:Thread: Medigene - nach Meldung hohe Umsätze auf Xetra

.
Das US-Biotech-Unternehmen Atrix Labs hat die Zulassung für Eligard erhalten.

Das Mittel zur Behandlung von Prostatakrebs im fortgeschrittenen Stadium ist bisher unter dem Namen Leuprogel bekannt.
Die Rechte für den Vertrieb in Nordamerika hat Atrix an den Pharmakonzern Sanofi-Synthelabo vergeben.
Artrix wird das Medikament produzieren und Tantiemen aus den Verkäufen erhalten.
Eine ähnliche Abmachung hat das Unternehmen mit der am Neuen Markt notierten Medigene AG geschlossen,
welche die europäischen Vertriebsrechte hält.

Das US-Biotech-Unternehmen Atrix Laboratories hat eine Meilensteinzahlung in Höhe von 3 Mio. Dollar erhalten. Diesen Betrag hat Sanofi-Synthelabo bezahlt, da das experimentelle Medikament Leuprogel in einer speziellen Dosierung einen weiteren Schritt zur Marktzulassung vollzogen hat.

Sanofi ist Lizenznehmer von Atrix und besitzt die Vermarktungsrechte von Leuprogel für die USA und Kanada. Leuprogel wird in diversen Studien zum Einsatz gegen Prostata-Krebs getestet.

Für sämtliche drei Dosierungen hat das am Neuen Markt notierte Unternehmen Medigene die europäischen Vermarktungsrechte erworben.
.
.


.
.
In August of 2000 Atrix announced a major agreement with Pfizer granting broad-based access to Atrix`s drug delivery technologies. Under the agreement, Pfizer will select appropriate compounds from its drug development pipeline to evaluate using Atrix`s unique parenteral, transmucosal, and topical delivery technologies. Any compound that can`t be delivered orally or could benefit from advanced drug delivery Pfizer brings to Atrix as a feasibility study. If a product is successfully commercialized from this alliance, Atrix will receive royalties on product sales and has the right to manufacture the product and receive a manufacturing margin as well. Atrix has 100 percent R&D funding from Pfizer, and several compounds in their drug delivery systems are currently being tested.


In June of 2000, Atrix formed a research joint venture with the Dublin-based pharmaceutical company Elan corporation. The partnership will focus on developing oncology-related and pain management products using Atrix`s patented BEMA™ and ATRIGEL® systems. The first compound to be developed in the joint venture was announced in October of 2000. Fentanyl, a potent opiate, will be developed in Atrix`s BEMA delivery technology for relief of cancer pain. In March 2001, Atrix announced that BEMA-emesis, for prevention and treatment of nausea associated with cancer chemotherapy, will be the second product to be developed in the Atrix/Elan joint venture. Both products are in preclinical trials. Atrix has total R&D funding from Elan, and performs all research using Atrix drug delivery technologies.


Atrix announced in January of 2001 that it entered into an exclusive North American marketing agreement with Sanofi-Synthélabo, a major international pharmaceutical company, for the 7.5 mg, 22.5 mg, and 30 mg Eligard™ products, leuprolide acetate for subcutaneous depot injection for the treatment of advanced prostate cancer. Under the agreement, valued at approximately $60 million, Atrix receives a license fee, R&D support and payments for certain clinical, regulatory and sales milestones. Atrix will also receive royalties based on sales of the Eligard products upon approval for marketing by the U.S. Food and Drug Administration (FDA). Sanofi-Synthélabo has a presence in more than 100 countries, and is a Top 20 global pharmaceutical company. Currently, they have 1000 U.S. sales representatives-a force which is expected to double by 2003. The company has 50 compounds in development, 26 of which are in Phase II or III.


Atrix signed a collaborative agreement with Novartis company--Geneva Pharmaceuticals, one of the largest marketers of generic prescription drug products in the U.S., to develop and manufacture prescription generic dermatology products. The alliance has targeted several products for development over a 10-year period. Geneva will market the products developed by Atrix under a profit sharing agreement. With several formulations in development, this collaboration represents another near-term revenue opportunity for Atrix.


In April 2001, Atrix entered into an exclusive European marketing agreement with MediGene AG, an emerging European leader in biotechnology for the Eligard Depot prostate cancer products. MediGene is an international biopharmaceutical company with five compounds in various stages of clinical development and core competence in oncology and cardiovascular disease.


In October 2001, Atrix announced that it licensed the exclusive North American marketing and distribution rights for its dermatological product, Atrisone™, dapsone topical gel, to Fujisawa Healthcare, Inc. Under the terms of the agreement, Atrix will receive up to $25 million in licensing fees, research and development support and milestone payments. Fujisawa will also pay Atrix royalties based on sales of the product. Atrix will manufacture Atrisone for Fujisawa in its Fort Collins facility and receive a manufacturing margine. Fujisawa Healthcare is a subsidiary of Fujisawa Pharmaceutical Col., Ltd., a leading global developer and marketer of dermatological and other proprietary pharmaceutical products.


In August 2001, Atrix announced that it licensed the exlusive U.S. marketing rights for Atridox®, Atrisorb®-Free Flow and Atrisorb®-D to CollaGenex Pharmaceuticals, Inc., the leader in prescription dental product sales. Under the terms of the agreement, Atrix received an up-front licensing fee of $1 million, and will receive a royalty on sales of the dental products plus a manufacturing margin from the production of the three products at its Fort Collins facility. CollaGenex has a sales force of approximately 120 sales reps and managers.




In April 2000, Atrix announced a license agreement with Pharmacia & Upjohn Animal Health for its periodontal therapy for companion animals. Pharmacia & Upjohn hold a
strong position in the companion animal dentistry market.
.
.

.
PRALL GEFÜLLTE PRODUKT-PIPLINE BEI ATRIX.
.


.
.

.

[Tortey]

@bilythekid superpräsentation!!!

weitere infos, einschätzungen, kursziele

für medigene 502090 findet ihr unter

Thread: MEDIGENE biotech-perle- wie es weiter geht !!!!

VIEL GLÜCK

[liebemachtblind]

SEHR SCHÖNER THREAD
Danke
Andy

[BillyTheKid2]

.
Die Umsätze steigen an der NASDAQ
.
Liegt wohl daran, dass der Wert langsam interessant wird.

Umsatz Nasdaq: 27.02.2002 = 144000 Stücke
.

.